News

The board of directors has approved the grant of 25,000 stock options.

The recording will be available for approximately 30 days.

This antibody-based nanomedicine format is hypothesized to have additional therapeutic benefits

Trading on the Nasdaq is expected to commence at market open on December 30, 2020.

Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159

We are inspired by the positive results from our initial preclinical studies evaluating PolyTope therapies against SARS-Cov-2